ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
{{output}}
Background: Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, the... ...